| | | Total | AF (+) | AF (−) | | | | |
| | Male gender, (%) | 254 (59.1%) | 34 (70.8%) | 220 (57.6%) | 0.109 | | Age, years, mean ± SD | | | | 0.086 | | ≤40 | 72 (16.8%) | 8 (16.6%) | 64 (16,7%) | 0.023 | | 41–65 | 191 (44.4%) | 15 (31.3%) | 176 (46.1%) | | >65 | 167 (38.8%) | 25 (52.1%) | 142 (34.2%) | | APACHE II, mean ± SD | | | | 0.090 | | ≤5 | 12 (2.8%) | 2 (4.2%) | 10 (2.6%) | 0.063 | | 6–10 | 93 (21.6%) | 4 (8.2%) | 89 (23.3%) | | 11–20 | 189 (43.9%) | 27 (56.3%) | 162 (42.4%) | | 21–30 | 103 (23.9%) | 8 (16.7%) | 95 (24.9%) | | >30 | 33 (7.8%) | 7 (14.6%) | 26 (6.8%) | | Admission etiology, (%) | — | — | — | — | | Trauma | 35 (8.1%) | 2 (4.2%) | 33 (8.6%) | 0.056 | | Medical | 196 (45.6%) | 24 (50%) | 172 (45.0%) | | Surgical, elective | 150 (34.9%) | 21 (43.7%) | 129 (33.8%) | | Surgical, urgency, nontrauma | 49 (11.4%) | 1 (2.1%) | 48 (12.6%) | | Comorbidities, (%) | — | — | — | — | | None | 64 (14.9%) | 5 (10.4%) | 59 (15.4%) | 0.479 | | Hypertension | 201 (46.7%) | 27 (56.2%) | 174 (45.5%) | 0.212 | | DM | 70 (16.3%) | 8 (16.7%) | 62 (16.2%) | 0.895 | | Cancer, actual | 69 (16.0%) | 6 (12.5%) | 63 (16.5%) | 0.616 | | Obesity (BMI ≥ 30) | 51 (11.9%) | 4 (8.3%) | 47 (12.3%) | 0.572 | | CHF functional class III or IV | 43 (10%) | 7 (14.6%) | 36 (9.4%) | 0.385 | | COPD | 34 (7.9%) | 6 (12.5%) | 28 (7.3%) | 0.332 | | CRF | 30 (7.0%) | 4 (8.3%) | 26 (6.8%) | 0.927 | | CRF with dialysis | 6 (1.4%) | 2 (4.2%) | 4 (1.0%) | 0.277 | | Severe neurological sequelae | 5 (1.2%) | 1 (2.1%) | 4 (1.0%) | 0.935 | | Smoking, actual or recent, (%) | 35 (8.1%) | 6 (12.5%) | 29 (7.6%) | 0.372 | | Alcohol use, actual or recent, (%) | 16 (3.7%) | 1 (2.1%) | 15 (3.9%) | 0.818 | | Complications, (%) | — | — | — | — | | ARF | 145 (33.7%) | 26 (54.2%) | 119 (31.2%) | 0.003 | | Dialysis | 38 (8.8%) | 9 (18.8%) | 29 (7.6%) | 0.022 | | ARDS | 77 (17.9%) | 14 (29.2%) | 63 (16.5%) | 0.050 | | Pneumonia | 74 (17.2%) | 15 (31.3%) | 59 (15.4%) | 0.011 | | Invasive MV | 228 (53.0%) | 27 (56.2%) | 201 (52.6%) | 0.747 | | Tracheostomy | 52 (12.1%) | 9 (18.8%) | 43 (11.2%) | 0.205 | | VAD use (any), (%) | 228 (53.0%) | 31 (64.6%) | 197 (51.6%) | 0.121 | | Dobutamine | 72 (16.7%) | 13 (27.1%) | 59 (15.4%) | 0.067 | | Dopamine | 4 (0.9%) | 0 | 4 (1.0%) | 0.928 | | Vasopressin | 14 (3.3%) | 0 | 14 (3.7%) | 0.360 | | Norepinephrine | 193 (44.9%) | 28 (58.3%) | 165 (43.2%) | 0.067 | | Total time Nor, days, mean ± SD | | | | 0.019 | | 0–2 | 316 (73.5%) | 27 (56.2%) | 289 (75.6%) | 0,007 | | >2 | 114 (26.5%) | 21 (43.8%) | 93 (24.4%) | | Maximal dose Nor (μg/kg/min), mean ± SD | | | | 0.004 | | 0–0,20 | 322 (74.9%) | 28 (58.3%) | 294 (77.0%) | 0.008 | | >0,20 | 108 (25.1%) | 20 (41.7%) | 88 (23.0%) | | Invasive MV, days, mean ± SD | 2.64 ± 5.33 | 4.43 ± 7.17 | 2.42 ± 5.02 | 0.014 | | 0 (no use) | 202 (47.0%) | 21 (43.8%) | 181 (47.4%) | 0.028 | | 1 | 81 (18.8%) | 5 (10.4%) | 76 (19.9%) | | 2–5 | 83 (19.3%) | 10 (20.8%) | 73 (19.1%) | | 6–10 | 37 (8.6%) | 5 (10.4%) | 32 (8.4%) | | >10 | 27 (6.3%) | 7 (14.6%) | 20 (5.2%) | | ICU mortality, (%) | 25.6% | 50% | 22.5% | <0.001 | | Hospital mortality, (%) | 30.2% | 52.08% | 27.5% | <0.001 |
|
|
